| Name | Title | Contact Details |
|---|
Quality Assurance Management is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Carrollton, TX. To find more information about Quality Assurance Management, please visit www.qam.com
EKR Therapeutics, Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Bedminster, NJ. To find more information about EKR Therapeutics, Inc., please visit www.ekrtx.com
Roundtrip is the leading digital transportation marketplace for better health outcomes. We provide a simple, comprehensive patient ride ordering software that makes available a community of ride providers who complete the transport. The company is leading the industry in reducing patient no-shows through improved ride management. Roundtrip is built for healthcare professionals — care coordinators, social workers, nurses and other transport requestors —and offers easy-to-use online and mobile platforms that connect patients with non-emergency medical transportation (NEMT). Roundtrip is a comprehensive solution which supports all levels of transport: medical cars, wheelchair vans, stretcher vehicles, ALS/BLS, all payors, and all trips delivered when and where they are needed. Roundtrip is doing more than expanding access to care; we are changing how people manage their health in their everyday lives. As we address social determinants of health and aging in place, Roundtrip is driven to deliver engaged and empowered transportation experiences for our riders.
Proprio is a Seattle company developing a system for real-time immersive video and mediated reality interaction. We are using cutting edge algorithms and custom hardware to enhance human capabilities in high precision activities such as brain surgery.
ContraVir is a biopharmaceutical company focused primarily on the development of drugs to treat herpes zoster, or shingles, which is an infection caused by the reactivation of varicella zoster virus or VZV. Our lead candidate, FV-100, is an orally available nucleoside analogue prodrug of CF-1743 that we are developing for the treatment of shingles. Published preclinical studies demonstrate that FV-100 is significantly more potent against VZV than acyclovir, valacyclovir, and famciclovir, the FDA-approved drugs used for the treatment of shingles. Preclinical studies further demonstrate that FV-100 has a more rapid onset of antiviral activity, and may fully inhibit the replication of VZV more rapidly than these drugs at significantly lower concentration levels. In addition, pharmacokinetic data from completed phase 1 and 2 clinical trials suggest that FV-100 has the potential to demonstrate antiviral activity when dosed orally once-a-day at significantly lower levels than valacyclovir, acyclovir, and famciclovir.